A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment
A phase 3 trial of Durvalumab in endometrial cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain is a phase 3 interventional study registered as NCT06746116 by AstraZeneca, with 45 participants enrolled, started 2024-12-30 and due to reach its primary completion in 2028-11-30. Interventions recorded: Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase. Conditions listed: Advanced or Recurrent Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca.
- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Durvalumab, AstraZeneca.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Durvalumab, AstraZeneca.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares Durvalumab, AstraZeneca.
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Durvalumab, AstraZeneca.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Durvalumab, AstraZeneca.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Durvalumab, AstraZeneca.